Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
15-Nov-2023
Removal from Official List
14-Nov-2023
Change in substantial holding
13-Nov-2023
Suspension from Official List
8-Nov-2023
Change in substantial holding
3-Nov-2023
Notice of Annual General Meeting/Proxy Form
2-Nov-2023
Preliminary update from ongoing Phase 2 Study of Paxalisib
31-Oct-2023
Proposed issue of securities - KZA
31-Oct-2023
Kazia announces short term unsecured Promissory Note
31-Oct-2023
Quarterly Activities/Appendix 4C Cash Flow Report
27-Oct-2023
Kazia SEC Form 20-F
1
2
3
4
5
6
7
8
9
Next
